Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases

Arthritis and Rheumatism

Volumn 40, Issue 6, 1997, Pages 1126-1129

  Nozawa, Kazuhisa ^a,b   Kayagaki, Nobuhiko ^a   Tokano, Yoshiaki ^a   Yagita, Hideo ^a   Okumura, Ko ^a   Hasimoto, Hiroshi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANTIGEN DETECTION; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CELL PROLIFERATION; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; RHEUMATIC DISEASE; STEROID THERAPY; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD95; ARTHRITIS, RHEUMATOID; CHILD; DERMATOMYOSITIS; FAS LIGAND PROTEIN; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; POLYMYOSITIS; REFERENCE VALUES; RHEUMATIC DISEASES; SJOGREN'S SYNDROME; SOLUBILITY;

EID: 0030916102     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400617     Document Type: Article

References (15)

1. Ju S, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444-448, 1995
2. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317, 1992
3. Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 3685-3692, 1994
4. Cheng J, Zhou T, Liu C: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762, 1994
5. Suda T, Tukahasi T, Golstain P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169-1178, 1993
6. Suda T, Okazaki T, Naito Y, Yokota T, Arai N, Ozaki S, Nakao K, Nagata S: Expression of the Fas ligand in cells of T cell lineage. J Immunol 154:3806-3813, 1995
7. Tanaka M, Suda T, Takahasi T, Nagata S: Expression of the functional soluble form of human Fas ligand in activated lymphocyte. EMBO J 14:1129-1136, 1995
8. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyosi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S: Fas ligand in human serum. Nature Medicine 2:319-322, 1996
9. Alarcón-Segovia D, Villareal M: Classification and diagnostic criteria for mixed connective tissue disease. In, Mixed Connective Tissue Disese and Antinucleur Antibodies. Edited by R Kasukawa, GC Sharp, Amsterdam, Elsevier, 1987
10. Bombardier C, Gladmann DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE: Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630-640, 1992
11. Littman BH, Druby CE, Zimmerer RO, Stack CB, Law CG: Rheumatoid arthritis treated with tenidap and piroxicam: clinical associations with cytokine modulation by tenidap. Arthritis Rheum 38:29-37, 1995
12. Cifone MG, Maria RD, Roncaioli P: Apoptotic signaling through CD95 (Fas/APO-1) activates an acidic sphingomyelinase. J Exp Med 177:1547-1552, 1994
13. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182:1777-1783, 1995
14. Knipping E, Krammer PH, Onel KB, Lehman TJA, Mysler E, Elkon KB: Levels of soluble Fas/APO-l/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 38:1735-1737, 1995
15. Goel N, Ulrich DT, St. Clair W, Fleming JA, Lynch DH, Seidin MF: Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 38:1738-1743, 1995